Literature DB >> 16204465

Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats.

Brendan M Johnson1, Peijin Zhang, John D Schuetz, Kim L R Brouwer.   

Abstract

Multidrug resistance-associated protein (Mrp) 2-deficient transport-deficient (TR(-)) rats, together with their transport-competent Wistar counterparts (wild type), have been used to examine the contribution of Mrp2 to drug disposition. However, little is known about potential variation in expression of other transport proteins between TR(-) and wild-type rats or whether these differences are tissue-specific. Sections of liver, kidney, brain, duodenum, jejunum, ileum, and colon were obtained from male TR(-) and wild-type Wistar rats. Samples were homogenized in protease inhibitor cocktail and ultracentrifuged at 100,000g for 30 min to obtain membrane fractions. Mrp2, Mrp3, Mrp4, P-glycoprotein, sodium-dependent taurocholate cotransporting polypeptide, organic anion transporting polypeptides 1a1 and 1a4, bile salt export pump, breast cancer resistance protein, ileal bile acid transporter, UDP-glucuronosyl transferase (UGT1a), glyceraldehyde-3-phosphate dehydrogenase, and beta-actin protein expression were determined by Western blot. Mrp3 was significantly up-regulated in the liver ( approximately 6-fold) and kidney ( approximately 3.5-fold) of TR(-) rats compared with wild-type controls. Likewise, the expression of UGT1a enzymes was increased in the liver and kidney of TR(-) rats by approximately 3.5- and approximately 5.5-fold, respectively. Interestingly, Mrp3 expression was down-regulated in the small intestine of TR(-) rats, but expression was similar to wild type in the colon. Mrp4 was expressed to varying extents along the intestine. Expression of some transport proteins and UGT1a enzymes differ significantly between TR(-) and wild-type rats. Therefore, altered drug disposition in TR(-) rats must be interpreted cautiously because up- or down-regulation of other transport proteins may play compensatory roles in the presence of Mrp2 deficiency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204465     DOI: 10.1124/dmd.105.005793

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  24 in total

1.  Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes.

Authors:  Nathan D Pfeifer; Kyunghee Yang; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2013-09-10       Impact factor: 4.030

2.  Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats.

Authors:  Brian T Hawkins; Scott M Ocheltree; Kristi M Norwood; Richard D Egleton
Journal:  Neurosci Lett       Date:  2006-11-15       Impact factor: 3.046

3.  N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.

Authors:  Lipeng Wang; Markos Leggas; Mamta Goswami; Philip E Empey; Patrick J McNamara
Journal:  Drug Metab Dispos       Date:  2008-09-17       Impact factor: 3.922

4.  Placental and fetal disposition of mercuric ions in rats exposed to methylmercury: role of Mrp2.

Authors:  Christy C Bridges; Lucy Joshee; Rudolfs K Zalups
Journal:  Reprod Toxicol       Date:  2012-10-08       Impact factor: 3.143

Review 5.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 6.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

7.  Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.

Authors:  María L Ruiz; Juan P Rigalli; Agostina Arias; Silvina Villanueva; Claudia Banchio; Mary Vore; Aldo D Mottino; Viviana A Catania
Journal:  Drug Metab Dispos       Date:  2012-10-17       Impact factor: 3.922

8.  Mechanistic Modeling of the Hepatic Disposition of Estradiol-17β-Glucuronide in Sandwich-Cultured Human Hepatocytes.

Authors:  Katsuaki Ito; Noora Sjöstedt; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-11-19       Impact factor: 3.922

9.  In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance.

Authors:  Koji Abe; Arlene S Bridges; Wei Yue; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2008-06-23       Impact factor: 4.030

10.  Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).

Authors:  Sonia R Miranda; Jin Kyung Lee; Kim L R Brouwer; Zhiming Wen; Philip C Smith; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-08-07       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.